Hepatocellular carcinoma (HCC) is the sixth most common cancer and the fourth leading cause of cancer-related death globally. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are the major risk factors accounting for 75% of all HCC cases. Currently, curative treatments including surgical resection and liver transplantation can only be applied to early diagnosed patients. For advanced HCC patients, the currently available first-line molecularly targeted medications showed limited survival benefits and low response...